Cubist Pharmaceuticals, Inc. / Optimer Pharmaceuticals, Inc.

Clostridioides difficile-Associated Diarrhea (CDAD/CDI)

500K US cases/yr

Disease Overview

C. difficile is a toxin-producing bacterium that causes severe colitis, most often after antibiotic exposure disrupts gut flora. With ~500,000 US cases annually and a 20–30% recurrence rate, CDI is one of the most consequential healthcare-associated infections, driving significant inpatient cost and mortality.

Competitive Landscape

At the time of the July 2013 Cubist-Optimer deal, CDAD treatment was dominated by oral vancomycin and metronidazole — both decades-old, cheap generics with high recurrence rates. Optimer's Dificid (fidaxomicin), FDA-approved in May 2011, was the first new CDAD antibiotic in over 25 years and the first macrocyclic narrow-spectrum agent — clinical trials showed non-inferior cure to vancomycin with ~50% lower recurrence, supporting a premium price point but limited initial uptake due to formulary cost barriers. Cubist had been Optimer's US co-promote partner since 2011, layering Dificid onto its existing Cubicin (daptomycin) hospital sales force; the buyout converted that arrangement into outright ownership and consolidated a hospital infectious-disease franchise. Competing assets at deal time included Sanofi/Merck's Cdiffense vaccine (Phase 3, later discontinued), Summit's ridinilazole, and Seres' microbiome candidate SER-109. Bezlotoxumab (Merck's Zinplava, anti-toxin B mAb) and Ferring/Rebiotix's Rebyota and Seres/Nestlé's Vowst microbiome therapeutics later expanded the recurrence-prevention category. Cubist itself was acquired by Merck in December 2014 for $9.5B, folding Dificid into Merck's hospital portfolio.